Literature DB >> 329769

Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy.

A R Ahmed, J C Maize, T T Provost.   

Abstract

Thirty-six patients with bullous pemphigoid (BP) have been periodically evaluated for four years. This study demonstrates that BP may occur in a transient predominantly localized form that remits spontaneously, and most BP patients after successful therapy remain in prolonged clinical remission. In this study, all patients with active or recurrent disease had IgG and/or C3 basement membrane zone (BMZ) deposition. Serum anti-BMZ antibodies was an inconstant feature. In most instances, clinical remission of BP was associated with disappearance of BMZ ig and C3 deposition and serum BMZ antibodies. Fluorescein-conjugated, antihuman C3 appears to be a more sensitive immunoreagent than antihuman, class specific, immunoglobulin antisera in detecting positive BMZ staining in BP. Combined therapy with azathioprine plus prednisone appears to be superior to prednisone alone in the treatment of BP.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 329769     DOI: 10.1001/archderm.113.8.1043

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  20 in total

Review 1.  Interventions for bullous pemphigoid.

Authors:  Gudula Kirtschig; Philippa Middleton; Cathy Bennett; Dedee F Murrell; Fenella Wojnarowska; Nonhlanhla P Khumalo
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  The skin in diabetes mellitus.

Authors:  M J Goodfield; L G Millard
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

4.  Antigen specificities of antibasement membrane zone antibodies: immunofluorescence and Western immunoblotting studies.

Authors:  T Muramatsu; T Shirai; T Iida; Y Yamashina; K Sakamoto
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

5.  Absence of anti-Ro and anti-La antibodies in pemphigus and pemphigoid sera.

Authors:  A R Ahmed
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

6.  Pemphigoid.

Authors: 
Journal:  Br Med J       Date:  1978-01-14

Review 7.  Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics.

Authors:  A Anstey
Journal:  J R Soc Med       Date:  1995-03       Impact factor: 5.344

8.  Interleukin-2 production in bullous pemphigoid.

Authors:  A R Ahmed; K Hijri; V Arab-Kermani
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

9.  Serum and blister fluid immune complexes in bullous pemphigoid: detection with C1q and monoclonal rheumatoid factor.

Authors:  R E Jordon; M F Struve; L L Bushkell
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

Review 10.  Autoimmune bullous dermatoses in the elderly: diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.